FDA approves Pebrilzo, but settlement delays Biocon’s U.S. launch
FDA approved Biocon’s Pebrilzo for HER2-positive breast cancer, with no clinically meaningful differences from Perjeta. A Genentech settlement defers U.S. launch until at least Q3 2028.
